No benefit from ramucirumab in first-line chemotherapy?
نویسندگان
چکیده
منابع مشابه
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients
BACKGROUND Macrophages play a crucial role in the interaction between tumor and immune system, and iNOS is known as a surrogate marker of M1 macrophages activation. The goal of the study was to investigate the role of iNOS polymorphisms as prognostic marker in mCRC patients. MATERIALS AND METHODS Functional significant polymorphisms in the promoter of INOS gene were analyzed by PCR-based and ...
متن کاملFirst-Line Chemotherapy for Advanced Breast Cancer.
First-line chemotherapy for metastatic breast cancer has been the focus of ongoing controversy, a condition that partially reflects the imperfections of available therapy. It also partially reflects not only the imperfections in our ability to monitor response, but also the disagreements among clinicians over the goals of therapy. Each physician maintains a hierarchy of goals for the treatment ...
متن کاملFirst line chemotherapy of metastatic breast cancer.
In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.
متن کاملFirst-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
n engl j med 371;23 nejm.org December 4, 2014 2167 From Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); State Key Laboratory of South China, Hong Kong Cancer Institute, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin (T. Mok), and Guangdong Lung Cancer Institute, Guangzhou (Y.-L.W.) — both in China; Seoul National University Hospital, Seoul, South Kor...
متن کاملFirst-line crizotinib versus chemotherapy in ALK-positive lung cancer.
BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown. METHODS We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Translational Gastroenterology and Hepatology
سال: 2017
ISSN: 2415-1289
DOI: 10.21037/tgh.2017.03.18